On July 17, 2008, Murray, Anthony; Lau, Jesper; Vedsoe, Per published a patent.Quality Control of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate The title of the patent was Preparation of arylureidothiazolylthioalkanoates as glucokinase activators. And the patent contained the following:
Title compounds [I; R = CH2CO2H, CH2CMe2CO2H, CMe2CO2H; R1 = substituted (heteroaryl-fused) Ph], were prepared for treatment of diabetes, hyperglycemia, obesity, syndrome X, dyslipidemia, and impaired glucose tolerance (no data). Thus, cyclopentylmethyl(2,5-difluorophenyl)amine (preparation given), Et 3-(2-aminothiazol-5-ylsulfanyl)-2,2-dimethylpropionate (preparation given), carbonyldiimidazole, and DMAP were stirred together in THF at 40-50° to give the desired urea ester, which was saponified with aqueous NaOH in THF/MeOH to give [2-[3-cyclopentylmethyl-3-(2,5-difluorophenyl)ureido]thiazol-5-ylsulfanyl]acetic acid. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Quality Control of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate
The Article related to arylcyclopentylmethylureidothiazolylthioalkanoate preparation glucokinase activator, diabetes hyperglycemia obesity dyslipidemia treatment thiazolylthioalkanoate ureido aryl cyclopentylmethyl and other aspects.Quality Control of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate
Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica